TD Cowen raises target for Natera stock to USD 480.00

Published on 10/14/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 752.75 million, up 37.70 percent. Natera stock costs EUR 355.50 on October 14, 2026.

Target change and operating growth

TD Cowen lifted its Natera target to USD 480.00 on October 13, 2026.
Second-quarter revenue reached USD 752.75 million, up 37.70 percent year over year.
Natera stock trades at EUR 355.50 at 1:17 p.m. CEST at Lang & Schwarz on October 14, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

TD Cowen raised its price target for Natera stock from USD 340.00 to USD 480.00 on October 13, 2026, while maintaining a Buy rating, as Markets Insider reported. The change puts the analyst view above Natera's latest US dollar market quote and keeps earnings execution at the center of the valuation debate.

Three developments shape the story

On October 13, 2026, Natera announced a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a colorectal cancer trial using Signatera to identify patients with molecular residual disease, according to Natera. The trial is being conducted within the PRE-I-SPY program.

On October 9, 2026, Natera received Breakthrough Device designation for its multi-cancer early detection assay, according to the company's related news listing. On August 6, 2026, the company reported second-quarter revenue of USD 752.75 million, up 37.70 percent from the prior-year quarter, and a GAAP net loss of USD 66.97 million, while adjusted earnings per share were not used in that comparison, according to Benzinga.

What does the guidance reset show?

Natera's second-quarter call described a revenue outlook of USD 2.85 billion to USD 2.91 billion for fiscal year 2026, implying 31.00 percent growth excluding revenue true-ups, according to Benzinga. Management also cited gross margin of approximately 65.00 percent in the quarter and a long-term target above 70.00 percent.

The numbers explain why analysts have moved their targets quickly: revenue growth is accelerating, while the company is still reporting a GAAP loss. MarketBeat said Natera's second-quarter EPS loss of USD 0.47 was better than the USD 0.49 consensus estimate, and its revenue exceeded the USD 661.24 million expectation, as MarketBeat reported.

Stock price remains the live reference

Natera stock was trading at EUR 355.50 at Lang & Schwarz on October 14, 2026, at 1:17 p.m. CEST. The company operates in healthcare and medical diagnostics, with its Nasdaq-listed business focused on cell-free DNA testing across oncology, women's health and organ health. The higher analyst target and the latest revenue outlook give investors two measurable reference points, but the GAAP loss remains part of the current financial picture. The further course of trading is shown by the continuously updated real-time quote of Natera stock.